Amicus Therapeutics Inc’s recent filing unveils that its President and CEO Campbell Bradley L unloaded Company’s shares for reported $87798.0 on Sep 03 ’24. In the deal valued at $11.71 per share,7,500 shares were sold. As a result of this transaction, Campbell Bradley L now holds 886,654 shares worth roughly $9.5 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, BRADLEY CAMPBELL bought 7,500 shares, generating $87,075 in total proceeds.
Before that, Campbell Bradley L sold 7,500 shares. Amicus Therapeutics Inc shares valued at $77,518 were divested by the President and CEO at a price of $10.34 per share. As a result of the transaction, Campbell Bradley L now holds 886,654 shares, worth roughly $9.5 million.
Jefferies initiated its Amicus Therapeutics Inc [FOLD] rating to a Buy in a research note published on September 06, 2024; the price target was $18. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who began to cover the stock in late May with a ‘”an Overweight”‘ rating. Guggenheim also remained covering FOLD and has increased its forecast on May 14, 2024 with a “Buy” recommendation from previously “Neutral” rating. Morgan Stanley revised its rating on December 19, 2023. It rated FOLD as “an Overweight” which previously was an “an Equal-weight”.
Price Performance Review of FOLD
On Friday, Amicus Therapeutics Inc [NASDAQ:FOLD] saw its stock fall -0.09% to $10.71. Over the last five days, the stock has lost -5.14%. Amicus Therapeutics Inc shares have fallen nearly -24.52% since the year began. Nevertheless, the stocks have fallen -16.85% over the past one year. While a 52-week high of $14.57 was reached on 01/02/24, a 52-week low of $9.02 was recorded on 05/13/24. SMA at 50 days reached $11.05, while 200 days put it at $11.43.
Levels Of Support And Resistance For FOLD Stock
The 24-hour chart illustrates a support level at 10.59, which if violated will result in even more drops to 10.48. On the upside, there is a resistance level at 10.85. A further resistance level may holdings at 10.99. The Relative Strength Index (RSI) on the 14-day chart is 38.89, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.32, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 74.77%. Stochastics %K at 19.04% indicates the stock is a buying.
How much short interest is there in Amicus Therapeutics Inc?
A steep rise in short interest was recorded in Amicus Therapeutics Inc stocks on 2024-09-13, dropping by -1.23 million shares to a total of 22.81 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-15 was 24.04 million shares. There was a decline of -5.41%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on September 09, 2022 when Morgan Stanley began covering the stock and recommended ‘”an Equal-weight”‘ rating along with a $14 price target.